181 related articles for article (PubMed ID: 18251284)
1. Guillain-Barré syndrome after treatment with sunitinib malate?
Mulherin B; Loconte NK; Holen KD
Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
[TBL] [Abstract][Full Text] [Related]
2. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
4. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Polyzos A
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
[TBL] [Abstract][Full Text] [Related]
5. [Management of sunitinib-associated adverse events].
Kanda H; Masui S; Yamada Y; Arima K; Sugimura Y
Hinyokika Kiyo; 2012 Nov; 58(11):639-46. PubMed ID: 23254793
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib-related fulminant hepatic failure: case report and review of the literature.
Mueller EW; Rockey ML; Rashkin MC
Pharmacotherapy; 2008 Aug; 28(8):1066-70. PubMed ID: 18657022
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
10. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in solid tumors.
Gan HK; Seruga B; Knox JJ
Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
[TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Saylor PJ; Reid TR
J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
[No Abstract] [Full Text] [Related]
13. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
15. Allergic interstitial nephritis possibly related to sunitinib use.
Khurana A
Am J Geriatr Pharmacother; 2007 Dec; 5(4):341-4. PubMed ID: 18179992
[TBL] [Abstract][Full Text] [Related]
16. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
[TBL] [Abstract][Full Text] [Related]
17. Blue toe syndrome and sunitinib.
Postema PG; Regeer MV; van der Valk PR; Stroes ES; Richel DJ
Int J Clin Oncol; 2011 Oct; 16(5):574-6. PubMed ID: 21136131
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib-related interstitial pneumonia after treatment with temsirolimus: a case of possible recall phenomenon.
Kushima H; Ishii H; Kadota J
Int J Urol; 2014 Apr; 21(4):420-1. PubMed ID: 24168290
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH
Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258
[TBL] [Abstract][Full Text] [Related]
20. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
[Next] [New Search]
